Rezera (RZRA.US) submits IPO application: Oral NLRP3 inhibitor pipeline progresses, Phase 3 PAD trial scheduled to begin in 2027

According to Golden Ten Data, Rezera is a biotechnology company ready for phase III clinical trials, developing oral NLRP3 inhibitors for inflammatory diseases. On Wednesday, the company filed for an IPO with the US Securities and Exchange Commission (SEC), with a proposed fundraising size of 100 million US dollars (placeholder figure) listed in the document.

Rezera is developing an oral inhibitor of NLRP3, an upstream driver of sterile inflammation, for the treatment of cardiovascular and neuroinflammatory diseases. Its core candidate drug, ruvonoflast, has completed two phase II trials for cardiometabolic diseases; the company plans to initiate a phase III trial for peripheral artery disease (PAD) in the first half of 2027, with data expected in 2028. The company is also developing trabzanoflast, a NLRP3 inhibitor capable of crossing the blood-brain barrier, which has completed a phase I trial for neuroinflammatory indications. The company retains global rights to all candidate drugs.

Founded in 2016, the company plans to list on Nasdaq under the ticker RZRA.US. Rezera secretly submitted a listing application on July 7, 2026. Jefferies, TD Securities, and Cantor Fitzgerald are acting as joint bookrunners for the offering. Pricing terms have not yet been disclosed.